{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Viridian Therapeutics, Inc.
Is Viridian Therapeutics, Inc. overvalued or undervalued?
As of November 13, 2023, Viridian Therapeutics, Inc. is considered overvalued and has been downgraded to "does not qualify" due to poor financial metrics and underperformance compared to peers and the S&P 500.
Is Viridian Therapeutics, Inc. technically bullish or bearish?
As of June 11, 2025, Viridian Therapeutics, Inc. exhibits a mildly bearish trend, supported by daily moving averages and monthly indicators, despite some conflicting signals from weekly metrics.
What does Viridian Therapeutics, Inc. do?
Viridian Therapeutics, Inc. is a micro-cap pharmaceutical and biotechnology company with no recent net sales and a net loss of $87 million as of March 2025. It has a market cap of approximately $1.21 billion and does not pay dividends.
How big is Viridian Therapeutics, Inc.?
As of Jun 18, Viridian Therapeutics, Inc. has a market capitalization of 1,210.42 million and reported net sales of 0.30 million with a net profit of -293.24 million over the latest four quarters. Shareholder's funds are 671.64 million, and total assets amount to 742.40 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
